background mycobacterium tuberculosi tuberculosi caus tuberculosi kill million infect peopl annual especi multidrugresist tuberculosi mdrtb infect macrophag recogn mycobacteria tolllik receptor tlr follow phagocytosi control mycobacteria addit macrophag also secret il12 induc ifn product which turn increas phagocytosi oxid burst individu defect innat adapt immun exhibit increas suscept tuberculosi understand immunolog mechan help control aim investig immunopatholog mechan mdrtb role recombin human interferongamma rhifn studi design method monocytederiv macrophag mdms were generat from peripher blood mononuclear cell mdrtb patient healthi subject were investig immunolog respons elisa flow cytometri result differ function molecular anomali were observ macrophag addit defect immun respons tuberculosi from patient mdms character which turn improv pretreat rhifn conclus this work highlight fact rhifn improv macrophag function against tuberculosi treatment patient poor respons therapi may need futur includ ifn adjuv therapi after full character patholog molecular mechan other more multidrugresist patient

Taj Ali Khan

Humaira Mazhar

Shamim Saleha

Hamid Nawaz Tipu

Niaz Muhammad

Muhammad Nasser Abbas

Interferon-Gamma Improves Macrophages Function against<i> M. tuberculosis</i> in Multidrug-Resistant Tuberculosis Patients

background the efficaci safeti cost benefit olanzapin oln when compar aprepit apr prevent chemotherapi induc nausea vomit cinv patient receiv high emetogen chemotherapi hec were evalu method prospect pilot studi done chemotherapyna patient receiv hec compar oln versus apr along palonosetron dexamethason 100 patient consent protocol were random evalu complet respons emesi rescu result 86 acut period 86 delay period 80 overal period 50 patient receiv apd regimen 84 acut period 88 delay period 78 overal period 50 patient receiv opd regimen patient without nausea were apd 88 acut 84 delay 84 overal opd 84 acut 88 delay 84 overal there were signific grade 3 4 toxic opd compar apd control cinv conclus studi signific differ between olanzapin aprepit prevent cinv high emetogen chemotherapi olanzapin may thus use potenti safe cost benefici altern prevent nausea vomit hec

Govind Babu

Smitha Carol Saldanha

Lakshmaiah Kuntegowdanahalli Chinnagiriyappa

Linu Abraham Jacob

Suresh Babu Mallekavu

Loknatha Dasappa

Pretesh Rohan Kiran

Aparna Sreevatsa

Sandhya Appachu

Vineetha Unnikrishnan

Venugopal Arroju

The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India

About this journal

Journal profile

Meet the editorial board

Editor spotlight

Submit your proposal

Do you think there is an emerging area of research that really needs to be highlighted? Or an existing research area that has been overlooked or would benefit from deeper investigation? Raise the profile of a research area by leading a Special Issue.

Special Issues

Chemotherapy Research and Practice

Published Special Issues

Chemotherapy Research and Practice

Table of Contents

Table of Contents: 2016

Interferon-Gamma Improves Macrophages Function against M. tuberculosis in Multidrug-Resistant Tuberculosis Patients

The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India